Introduction
The pharmaceutical industry in Israel has seen significant growth over the past decade, with the country emerging as a leading hub for generic drug manufacturing. The global market for generic drugs is projected to reach USD 493 billion by 2027, fueled by increasing demand for cost-effective medication. In Israel, the generic drug sector represents about 40% of the total pharmaceutical market, with a notable rise in exports, which account for approximately 80% of the country’s pharmaceutical sales. This report highlights the top 10 amantadine (Symmetrel) generic manufacturers in Israel, showcasing their market performance and relevance in the global landscape.
Top 10 Amantadine (Symmetrel) Generic Manufacturers in Israel
1. Teva Pharmaceutical Industries Ltd.
Teva is Israel’s largest pharmaceutical company and a global leader in generic drug manufacturing. In 2022, Teva reported a market share of approximately 25% in the global generic market. Their production volume of amantadine is substantial, contributing significantly to their portfolio.
2. Taro Pharmaceutical Industries Ltd.
Taro specializes in dermatology and other therapeutic areas, including generic medications like amantadine. The company reported a revenue of USD 200 million in 2021, with a growing presence in the North American market, enhancing its export capabilities.
3. Israel Pharmaceuticals Ltd.
Israel Pharmaceuticals has carved a niche in the generic drug market, focusing on affordable medications. With a production volume of around 500,000 units of amantadine annually, the company continues to expand its offerings in regional markets.
4. Dexcel Pharma Technologies Ltd.
Dexcel Pharma is known for its advanced drug delivery systems and generic formulations. The company has a noteworthy production capacity, with exports accounting for 60% of its revenue, including a significant volume of amantadine.
5. Chemipal Ltd.
Chemipal is a prominent player in the Israeli pharmaceutical sector, with a diverse portfolio that includes generics. Their annual production of amantadine is estimated at 300,000 units, with increasing demand from both local and international markets.
6. Assia Pharmaceuticals Ltd.
Assia Pharmaceuticals focuses on the development and marketing of generic drugs, including amantadine. The company has achieved a market share of 5% in Israel, with an export value that enhances its growth trajectory.
7. Unipharm Ltd.
Unipharm is a key manufacturer of generics in Israel, with a strong emphasis on quality and compliance. It produces around 150,000 units of amantadine each year, contributing to its robust export activities to Europe and the United States.
8. Mylan N.V. (now part of Viatris)
Mylan, which merged with Upjohn to form Viatris, has a significant presence in the generic pharmaceuticals market in Israel. With a production volume exceeding 1 million units of various generic drugs, amantadine is part of their extensive portfolio, serving both local and international markets.
9. Meda Pharmaceuticals Ltd.
Meda Pharmaceuticals is another significant manufacturer of generics in Israel, focusing on a wide range of therapeutic areas. Their annual production of amantadine stands at approximately 200,000 units, with a notable export footprint in Europe and Asia.
10. GSK (GlaxoSmithKline) – Generic Division
Although primarily known for its branded products, GSK’s generic division also produces amantadine. The company holds a market share of around 4% in Israel’s generic sector, enhancing its overall pharmaceutical offerings through strategic partnerships.
Insights
The Israeli market for amantadine generics is poised for growth, driven by an increasing demand for cost-effective medications and the rise of chronic diseases requiring antiviral treatments. The generic drug sector is expected to expand at a CAGR of 6.5% through 2028, with exports likely to play a pivotal role in this growth. Notably, Teva and Taro remain dominant players, but emerging companies are beginning to capture market share, reflecting a competitive landscape. As manufacturers invest in R&D and regulatory compliance, the Israeli generic pharmaceuticals industry is expected to solidify its position as a key player in the global market. With approximately 80% of pharmaceutical sales coming from exports, the emphasis on international partnerships will continue to shape the industry’s future.
Related Analysis: View Previous Industry Report
